Literature DB >> 19885660

Liver enzyme abnormalities in systemic lupus erythematosus: a focus on toxic hepatitis.

Minyoung Her1, YounJae Lee, EunUk Jung, TaeHee Kim, Dongyook Kim.   

Abstract

Although subclinical liver disease is common in systemic lupus erythematosus (SLE), strikingly high levels of liver enzymes are rare. Our aim was to determine the cause of high levels of liver enzymes in lupus patients, particularly in patients diagnosed with toxic hepatitis. We performed a retrospective chart review of SLE patients treated at the Inje University Hospital between 2001 and 2008. We defined liver enzyme abnormality as a twofold or greater increase in two or more of the following four components: total bilirubin, AST, ALT and LDH or ALP. Acute toxic hepatitis was diagnosed by a score ≥ 5 in the Roussel Uclaf Causality Assessment Method. Of 141 SLE patients 46 (32.6%) met strict criteria for the liver enzyme abnormality. In total, 11 patients (7.8%) in this study had presumed toxic hepatitis associated with either herbal medicines (n = 6), anti-tuberculosis medications (n = 3), antibiotics (n = 1) or valproic acid (n = 1). There were striking laboratory abnormalities in the groups diagnosed with toxic hepatitis (mean peak values: AST 775 ± 464 U/L, ALT 400 ± 447 U/L, ALP 767 ± 408 U/L, LDH 1,469 ± 779 U/L). All six patients with herbal-induced toxic hepatitis were in the active SLE state. After cessation of the suspected causative medication and subsequent administration of steroids, liver enzyme levels were improved. Herbal medicines and anti-tuberculosis medications, known to cause toxic hepatitis, can also induce increased liver enzyme levels in lupus patients. However, since most herbal medicines contain a mixture of various products, we could not ascertain what specific ingredient induced the increase in liver enzyme levels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19885660     DOI: 10.1007/s00296-009-1237-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  18 in total

Review 1.  Herbal hepatotoxicity.

Authors:  Felix Stickel; Eleonora Patsenker; Detlef Schuppan
Journal:  J Hepatol       Date:  2005-08-25       Impact factor: 25.083

2.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 4.  Herbal hepatotoxicity: an expanding but poorly defined problem.

Authors:  S Chitturi; G C Farrell
Journal:  J Gastroenterol Hepatol       Date:  2000-10       Impact factor: 4.029

5.  Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge.

Authors:  C Benichou; G Danan; A Flahault
Journal:  J Clin Epidemiol       Date:  1993-11       Impact factor: 6.437

6.  Prevention of autoantibody formation and prolonged survival in New Zealand Black/New Zealand White F1 mice with an ancient Chinese herb, Ganoderma tsugae.

Authors:  N S Lai; R H Lin; R S Lai; U C Kun; S C Leu
Journal:  Lupus       Date:  2001       Impact factor: 2.911

Review 7.  Autoimmune hepatitis triggered by administration of an herbal medicine.

Authors:  T Kamiyama; T Nouchi; S Kojima; N Murata; T Ikeda; C Sato
Journal:  Am J Gastroenterol       Date:  1997-04       Impact factor: 10.864

Review 8.  Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists.

Authors:  Raúl-J Andrade; Mercedes Robles; Alejandra Fernández-Castañer; Susana López-Ortega; M-Carmen López-Vega; M-Isabel Lucena
Journal:  World J Gastroenterol       Date:  2007-01-21       Impact factor: 5.742

9.  Subclinical liver disease in systemic lupus erythematosus.

Authors:  T Gibson; A R Myers
Journal:  J Rheumatol       Date:  1981 Sep-Oct       Impact factor: 4.666

Review 10.  Systematic review: hepatotoxic events associated with herbal medicinal products.

Authors:  M H Pittler; E Ernst
Journal:  Aliment Pharmacol Ther       Date:  2003-09-01       Impact factor: 8.171

View more
  9 in total

1.  Systemic lupus erythematosus and autoimmune hepatitis.

Authors:  Cumali Efe; Tugrul Purnak; Ersan Ozaslan
Journal:  Rheumatol Int       Date:  2010-07-28       Impact factor: 2.631

Review 2.  Herbal medicine for rheumatic diseases: promises kept?

Authors:  Sharon L Kolasinski
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

Review 3.  Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis.

Authors:  Fernando Bessone; Natalia Poles; Marcelo G Roma
Journal:  World J Hepatol       Date:  2014-06-27

Review 4.  Clinical Characteristics of Concomitant Systemic Lupus Erythematosus and Primary Biliary Cirrhosis: A Literature Review.

Authors:  Toru Shizuma
Journal:  J Immunol Res       Date:  2015-05-18       Impact factor: 4.818

5.  Acute oral toxicity and biodistribution study of zinc-aluminium-levodopa nanocomposite.

Authors:  Aminu Umar Kura; Bullo Saifullah; Pike-See Cheah; Mohd Zobir Hussein; Norazrina Azmi; Sharida Fakurazi
Journal:  Nanoscale Res Lett       Date:  2015-03-01       Impact factor: 4.703

Review 6.  Impact of Liver Functions by Repurposed Drugs for COVID-19 Treatment.

Authors:  Rongzhi Zhang; Qiang Wang; Jianshe Yang
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

7.  Morbidity and Mortality in Iranian Children with Juvenile Systemic Lupus erythematosus.

Authors:  Fariba Tavangar-Rad; Vahid Ziaee; Mohammad-Hassan Moradinejad; Fatemeh Tahghighi
Journal:  Iran J Pediatr       Date:  2014-07-01       Impact factor: 0.364

8.  A Male Patient With Systemic Lupus Erythematosus Presenting With Fulminant Hepatitis.

Authors:  Sukran Erten; Aylin Demirezer Bolat; Fatma Ebru Akin; Osman Ersoy
Journal:  Gastroenterology Res       Date:  2011-11-20

9.  The Role of MECP2 and CCR5 Polymorphisms on the Development and Course of Systemic Lupus Erythematosus.

Authors:  Ewa Rzeszotarska; Anna Sowinska; Barbara Stypinska; Ewa Walczuk; Anna Wajda; Anna Lutkowska; Anna Felis-Giemza; Marzena Olesinska; Mariusz Puszczewicz; Dominik Majewski; Pawel Piotr Jagodzinski; Michal Czerewaty; Damian Malinowski; Andrzej Pawlik; Malgorzata Jaronczyk; Agnieszka Paradowska-Gorycka
Journal:  Biomolecules       Date:  2020-03-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.